EXHIBIT 99

KV PHARMACEUTICAL COMPANY

                                           CONTACT:
                                           CATHERINE M. BIFFIGNANI
                                           VICE PRESIDENT, INVESTOR RELATIONS
                                           314-645-6600

                                           [KV PHARMACEUTICAL logo]

FOR IMMEDIATE RELEASE

              KV SIGNS LICENSING AGREEMENT FOR THE MARKETING OF
               CLINDESSE(TM) IN 18 EASTERN EUROPEAN COUNTRIES

               AGREEMENT AUGMENTS EXISTING PARTNERSHIP FOR THE
                  INTERNATIONAL MARKETING OF GYNAZOLE-1(R)

St. Louis, MO - December 1, 2005 - KV Pharmaceutical Company (NYSE: KVa/KVb)
announced today that it has concluded a long-term licensing agreement with
Gedeon Richter to market in 18 Eastern European countries KV's Clindesse(TM)
(clindamycin phosphate) vaginal cream 2% a single-dose prescription
treatment for bacterial vaginosis.

The agreement marks the growing relationship between KV and Gedeon Richter,
which includes an international license to market KV's one-dose prescription
cream treatment for vaginal yeast infection, Gynazole-1(R) (butoconazole
nitrate) vaginal cream 2%.

Gedeon Richter is one of the leading pharmaceutical companies in
Central/Eastern Europe as well as in the republics of the former Soviet
Union.

This agreement grants Gedeon Richter the rights to market Clindesse(TM) in
18 Eastern European countries. Under the terms of the license, KV will
receive upfront and milestone payments, as well as revenues on the sales of
the product. Clindesse(TM), which utilizes KV's proprietary drug delivery
system Site Release(R), was launched in January 2005 in the U.S. by Ther-Rx
Corporation, KV's branded marketing subsidiary.

Marc S. Hermelin, Vice Chairman and Chief Executive Officer of KV
Pharmaceutical stated, "We have an excellent and growing relationship with
Gedeon Richter and look forward to working together on future projects as
well. This new agreement also marks the introduction of Clindesse(TM) into
Eastern Europe, a territory which we have just recently entered with the
launch of Gynazole-1(R). Clindesse(TM) has already captured approximately
18% of the U.S. intra-vaginal cream marketplace in the bacterial vaginosis





category according to IMS America data - an outstanding accomplishment in
just 10 months since its launch."

Mr. Hermelin continued, "Through the first two quarters of fiscal year 2006,
Ther-Rx's anti-infective franchise has shown strong performance.
Clindesse(TM) has become the fastest growing branded intra-vaginal
prescription product to treat bacterial vaginosis in the United States.
Separately, Gynazole-1(R) currently maintains a 30% share of the
intra-vaginal prescription cream treatment which has resulted in almost one
of every three prescriptions filled for an intra-vaginal cream product for
the treatment of vulvovaginal candidiasis (VVC, commonly referred to as
yeast infections) being filled with Gynazole-1(R)."

Erik Bogsch, CEO of Gedeon Richter stated "The agreement with KV perfectly
fits Richter's strategy to strengthen our women's healthcare portfolio
especially in the Central-Eastern European and CIS countries. Richter has a
well established corporate image and a strong market position in this
region. Clindesse(TM) will contribute to our efforts to offer complex
therapies in the women's healthcare niche."

Vaginal infections are among the most common ailments for women.
Approximately 10 million doctor visits per year are due to vaginitis in the
US. Many current therapies in this treatment area require multiple days of
dosing, or have common side effects. These deficiencies could potentially
lead to decreased compliance or efficacy. Leveraging KV's proprietary Site
Release(R), Clindesse(TM) and Gynazole-1(R) were both designed to remain at
the site of infection providing minimum leakage, minimum systemic absorption
and any time administration.

Clindesse(TM) is the only approved bacterial vaginosis (BV) treatment with
convenient one-time dosing. Other BV treatments require a course of 3 to 10
doses. Clindesse(TM) is packaged in an easy-to-use, pre-filled applicator.
This combination, one-dose therapy in a pre-filled applicator provides
outstanding convenience and can help facilitate compliance with therapy.
Additionally, side effects with Clindesse(TM) were found similar to placebo.

Additional Safety Information about Gynazole-1(R) and Clindesse(TM):

GYNAZOLE-1(R) (BUTOCONAZOLE NITRATE) VAGINAL CREAM 2%

Gynazole-1(R) is indicated for the local treatment of vulvovaginal
candidiasis. The diagnosis should be confirmed by the KOH smears and/or
cultures. Gynazole-1(R) is safe and effective in non-pregnant women;
however, the safety and effectiveness in pregnant women has not been
established.

Gynazole-1(R) is contraindicated in patients with a history of
hypersensitivity to any of the components in the product.

                                   - 2 -




Gynazole-1(R) contains mineral oil, which may weaken latex or rubber
products such as condoms or vaginal contraceptive diaphragms; therefore, use
of such products within 72 hours following treatment with Gynazole-1(R) is
not recommended. Recurrent vaginal yeast infections, especially those that
are difficult to eradicate, can be an early sign of infection with the human
immunodeficiency virus (HIV) in women who are considered at risk for HIV
infection. If clinical symptoms persist, tests should be repeated to rule
out other pathogens, to confirm original diagnosis, and to rule out other
conditions that may predispose a patient to recurrent vaginal fungal
infections.

CLINDESSE(TM) (CLINDAMYCIN PHOSPHATE) VAGINAL CREAM, 2%

Clindesse(TM) is contraindicated in individuals with a history of
hypersensitivity to clindamycin, lincomycin, or any of the components of
this vaginal cream, and in individuals with a history of regional enteritis,
ulcerative colitis, or a history of "antibioitic-associated" colitis. There
are no adequate and well controlled studies of Clindesse(TM) in pregnant
women.

Clindesse(TM) contains mineral oil that may weaken latex or rubber products
such as condoms or vaginal contraceptive diaphragms. Therefore, the use of
such barrier contraceptives is not recommended concurrently or for 5 days
following treatment with Clindesse(TM). During this time period, condoms may
not be reliable for preventing pregnancy or for protecting against
transmission of HIV or other sexually transmitted diseases.

Pseudo membranous colitis has been reported with nearly all antibacterial
agents, including clindamycin. Orally and parenterally administered
clindamycin has been associated with severe colitis. Therefore, it is
important to consider this diagnosis in patients who present with diarrhea
subsequent to the administration of clindamycin, even though there is
minimal systemic absorption of clindamycin from the vagina with
administration of Clindesse(TM) cream.

In clinical trials totaling 368 women associated with a single dose of
Clindesse(TM), 1.6% of the patients discontinued therapy due to adverse
events. The most frequently reported adverse events were vaginosis fungal
(14.1%), vulvovaginal pruritus (3.3%), and headache (2.7%).

ABOUT KV PHARMACEUTICAL COMPANY

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical
company that develops, manufactures and markets and acquires
technology-distinguished branded and generic/non-branded prescription
pharmaceutical products. The Company markets its technology distinguished
products through ETHEX Corporation, a national leader in pharmaceuticals
that compete with branded products, and Ther-Rx Corporation, its


                                   - 3 -




emerging branded drug subsidiary. KV has consistently ranked as one of
America's fastest growing small companies, most recently by Forbes' in its
November 2004 issue.

For further information about KV Pharmaceutical Company, please visit the
Company's corporate website at www.kvpharmaceutical.com.

ABOUT GEDEON RICHTER LIMITED

Gedeon Richter Ltd., (www.richter.hu) headquartered in Budapest/Hungary, is
the leading pharmaceutical company in Hungary and one of the largest in
Central Eastern Europe, with more than 3 billion US$ market capitalization.
The company was founded in 1901. Gedeon Richter Ltd. plays the role of a
regional multinational company in Central Eastern Europe and in the CIS, and
has a growing presence through its commercial subsidiaries in key EU
countries, and the USA. Two thirds of its annual sales of more than 599
million USD in 2004 are exported to 80 countries (EU, USA, Japan, Russia
etc.) The company has a worldwide presence through its representative
offices, subsidiaries in 30 countries. It has production facilities in
Russia and Romania and Poland and there is one under construction in India.
The product portfolio of the company includes more than 100 products and
covers almost all important therapeutic areas. Based on its traditional
skills in steroid chemistry, the company is a significant player in the
gynaecological field worldwide. A significant part of the company's turnover
results from original drug research and development activity.

SAFE HARBOR

The information in this release may contain various forward-looking
statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include
assumptions concerning KV's operations, future results and prospects. Such
statements may be identified by the use of words like "plans", "expect",
"aim", "believe", "projects", "anticipate", "commit", "intend", "estimate",
"will", "should", "could" and other expressions that indicate future events
and trends.

All statements that address expectations or projections about the future,
including without limitation, statements about the Company's strategy for
growth, product development, regulatory approvals, market position,
expenditures and financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are
subject to risk and uncertainties. In connection with the "safe harbor"
provisions, KV provides the following cautionary statements identifying
important economic, political and technology factors which, among others,
could cause actual results or events to differ materially from those set
forth or implied by the forward-looking statements and related assumptions.

                                   - 4 -




Such factors include (but are not limited to) the following: (1) changes in
the current and future business environment, including interest rates and
capital and consumer spending; (2) the difficulty of predicting FDA
approvals, including timing, and that any period of exclusivity may not be
realized; (3) acceptance and demand for new pharmaceutical products; (4) the
impact of competitive products and pricing; (5) new product development and
launch including but not limited to the possibility that any product launch
may be delayed or that product acceptance may be less than anticipated; (6)
reliance on key strategic alliances; (7) the availability of raw materials;
(8) the regulatory environment; (9) fluctuations in operating results; (10)
the difficulty of predicting international regulatory approvals, including
timing; (11) the difficulty of predicting the pattern of inventory movements
by the Company's customers; (12) the impact of competitive response to the
Company's sales, marketing and strategic efforts; (13) risks that the
Company may not ultimately prevail in litigation; and (14) the risks
detailed from time to time in the Company's filings with the Securities and
Exchange Commission.

This discussion is by no means exhaustive, but is designed to highlight
important factors that may impact the Company's outlook. We are under no
obligation to update any of the forward-looking statements after the date of
this report.


                                   - 5 -